Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Produtos da "Sinalização JAK/STAT"
Ordenar por
Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Fórmula:C20H18FN5O3Pureza:98.05%Cor e Forma:SolidPeso molecular:395.39Pim-1/2 kinase inhibitor 1
CAS:Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.Fórmula:C11H9NO3SPureza:99.89%Cor e Forma:SolidPeso molecular:235.26JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Fórmula:C20H18FN5O3SPureza:98.88%Cor e Forma:SolidPeso molecular:427.45Ref: TM-T13571
1mg87,00€5mg177,00€10mg260,00€25mg429,00€50mg605,00€100mg815,00€500mg1.624,00€1mL*10mM (DMSO)188,00€JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Fórmula:C17H19F2N7OSPureza:98%Cor e Forma:SolidPeso molecular:407.44Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Cor e Forma:SolidPeso molecular:504.49ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Fórmula:C25H33N5O2Cor e Forma:SolidPeso molecular:435.56TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFórmula:C28H32N4O3SPureza:97.38% - 99.1%Cor e Forma:SolidPeso molecular:504.64(2R)-Octyl-α-hydroxyglutarate
CAS:(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a D-isomer 2-Hydroxyglutarate modified form.Fórmula:C13H24O5Cor e Forma:SolidPeso molecular:260.33Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H21ClFN7Pureza:99.55%Cor e Forma:SolidPeso molecular:425.89Ref: TM-T12266L2
1mg77,00€5mg165,00€10mg240,00€25mg408,00€50mg562,00€100mg800,00€200mg1.074,00€1mL*10mM (DMSO)177,00€G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Fórmula:C22H19F2NO3Pureza:97.30%Cor e Forma:SolidPeso molecular:383.39Ref: TM-T8742
1mg50,00€5mg97,00€10mg145,00€25mg259,00€50mg374,00€100mg523,00€200mg710,00€1mL*10mM (DMSO)105,00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Fórmula:C16H13Cl2N3O2Pureza:98.77%Cor e Forma:SolidPeso molecular:350.2RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFórmula:C17H14Cl2N6OPureza:97.94%Cor e Forma:SolidPeso molecular:389.24Ref: TM-T22416
1mg64,00€2mg87,00€5mg117,00€10mg183,00€25mg354,00€50mg520,00€100mg702,00€200mg944,00€1mL*10mM (DMSO)140,00€JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Fórmula:C27H32ClFN6OCor e Forma:SolidPeso molecular:511.03Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Cor e Forma:SolidPeso molecular:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Fórmula:C28H38N6O5SPureza:98%Cor e Forma:SolidPeso molecular:570.7SGI-1776
CAS:SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.Fórmula:C20H22F3N5OPureza:100% - 99.84%Cor e Forma:SolidPeso molecular:405.42Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Fórmula:C25H26F2N6O2Pureza:98.71%Cor e Forma:SoildPeso molecular:480.51Ref: TM-T67907
1mg96,00€2mg139,00€5mg227,00€10mg354,00€25mg653,00€50mg938,00€100mg1.454,00€500mg2.822,00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Fórmula:C14H10ClN3OS2Pureza:99.38%Cor e Forma:SolidPeso molecular:335.83JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Fórmula:C25H32N8O2Pureza:99.64%Cor e Forma:SolidPeso molecular:476.57WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Cor e Forma:SolidPeso molecular:356.22
